3Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross- reactivity: fact or fiction? [ J]. Ann Pharmacother, 2005, 39 (2) :290-301.
4Patterson R, Bello AE, Leikowith J. Immunologic tolerability profile of celecoxib[ J]. Clin Ther, 1999, 21 (12) :2065-2079.
5Knowles S, Shapiro L, Shear NH. Should celecoxib be contrain- dicated in patients who are allergic to sulfonamides? Revisiting the meaning of ulfa' allergy[J]. Drug Saf, 2001,24(4) :239-247.
6Harle DG, Baldo BA, Wells JV. Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethox- azole[ J]. Mol lmmunol, 1988, 2,5(12) : 1347-1354.
7Carrington DM, Earl HS, Sullivan TJ. Studies of human IgE to a sulfonamide determinant [ J ]. J Allergy Clin Immunol, 1987, 79 ( 3 ) :442-447.
8Trepanier LA. Idiosyncratic toxicity associated with potentia- ted sulfonamides in the dog[ J ]. J Vet Pharmacol Ther, 2004, 27 (3) :129-138.
9Nassif A, Bensussan A, Doroth6e G, Mami-Chouaib F, Bachot N, Bagot M, eta/. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis [ J ]. J Invest Dermatol, 2002, 118(4) :728-733.
10Tzanakis N, Metzidaki G, Thermos K, Spyraki CH, Bouros D. Anaphylactic shock after a single oral intake of acetazolamide [ J ]. Br J Ophthalmol, 1998, 82(5 ) :588.
